Pneumococcal Vaccines: Past Findings, Present Work... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies

Full text
Author(s):
Oliveira, Giuliana S. [1] ; Oliveira, Maria Leonor S. [1] ; Miyaji, Eliane N. [1] ; Rodrigues, Tasson C. [1]
Total Authors: 4
Affiliation:
[1] Inst Butantan, Lab Bacteriol, BR-05503900 Sao Paulo, SP - Brazil
Total Affiliations: 1
Document type: Review article
Source: VACCINES; v. 9, n. 11 NOV 2021.
Web of Science Citations: 0
Abstract

The importance of Streptococcus pneumoniae has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development of pneumococcal conjugate vaccines (PCV) caused an enormous impact in invasive pneumococcal disease and protected unvaccinated people by herd effect. However, serotype replacement is a well-known phenomenon that has occurred after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) and has also been reported for other PCVs. Therefore, it is possible that serotype replacement will continue to occur even with higher valence formulations, but the development of serotype-independent vaccines might overcome this problem. Alternative vaccines are under development in order to improve cost effectiveness, either using proteins or the pneumococcal whole cell. These approaches can be used as a stand-alone strategy or together with polysaccharide vaccines. Looking ahead, the next generation of pneumococcal vaccines can be impacted by the new technologies recently approved for human use, such as mRNA vaccines and viral vectors. In this paper, we will review the advantages and disadvantages of the addition of new polysaccharides in the current PCVs, mainly for low- and middle-income countries, and we will also address future perspectives. (AU)

FAPESP's process: 17/26090-7 - Nanoparticle pulmonary vaccine formulation based on lipossomes containing protein antigens from Streptococcus pneumoniae
Grantee:Tasson da Costa Rodrigues
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 18/25165-6 - Role of antibodies against PspA and PspC variants in the protection against Streptococcus pneumoniae
Grantee:Eliane Namie Miyaji
Support Opportunities: Regular Research Grants
FAPESP's process: 19/15961-2 - Caracterization of immune response to vaccines against Streptococcus pneumoniae in mice selected for high and low acute inflammatory responses
Grantee:Giuliana Stephani de Oliveira
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 19/06190-2 - Evaluation of the immune response to vaccines against Streptococcus pneumoniae in mice with high susceptibility to infection
Grantee:Maria Leonor Sarno de Oliveira
Support Opportunities: Regular Research Grants
FAPESP's process: 21/04996-0 - Interaction of Streptococcus pneumoniae, extracellular vesicles and nanoparticles with cells using respiratory tract epithelium models
Grantee:Eliane Namie Miyaji
Support Opportunities: Regular Research Grants